Pro 2013-021 (Jianfeng Group Corporate Bond Listing Announcement)-3
Release time:
2020-08-05
Section III Overview of Bond Issuance
1. Bond Name
Zhejiang Jianfeng Group Co., Ltd. 201 3 Corporate Bonds (Phase I) (hereinafter referred to as "13 Peak 01 " ).
2. Bond Issuance Approval Authority and Document No.
This issue of bonds has been approved by China Securities Regulatory Commission Securities Regulatory License [201 3 ] 595 .
Total 3. Bond Issue
The size of the bond issue is 3 .7 billion yuan.
4. The maturity of this bond variety
The maturity of this corporate bond is 5 years (with 3 end-of-year issuer interest rate increase option and investor resale option).
5. Bond Issuance Method and Issuance Object
(I) Issuance Method
This issue of bonds adopts a combination of online public offering for public investors and offline inquiry agreement placement for institutional investors. Online subscription is concluded in real time according to the principle of "time first" , and offline subscription is conducted in the form of the issuer and the sponsor (lead underwriter) sending a "Placing Payment Notice" to institutional investors or signing an "offline subscription agreement" with them.
(II) Issuing Object
() Online Issuing: Public Investors (except those prohibited by laws and regulations) who hold the securities accounts of A , B , D and F opened by the registration institution.
( 2 ) Offline: Institutional investors who open qualified securities accounts with a registrar (except where purchasers are prohibited by laws and regulations).
6. the lead underwriter and members of the underwriting syndicate
The bonds are underwritten by the sponsor (lead underwriter) Zheshang Securities Co., Ltd. by way of balance underwriting.
The sponsor and lead underwriter of the bonds are Zheshang Securities Co.
7. bond denominationcurrent bond denomination
100 yuan, issued at par value.
8. Bond Annual Interest Rate, Interest Rate and Debt Repayment MethodThe coupon rate of the current bond is
4.90 % , using single interest on an annual basis, excluding compound interest. Interest is paid once a year, the principal is repaid once due, and the last interest is paid with the payment of the principal. The interest payment and principal payment of the bonds shall be handled in accordance with the relevant business rules of the registered company.
The interest date of this bond is2013 6 April 5 , Interest Payment Date is 2006 to 2018 on June 6 5 of each year (in case of legal holidays or rest days postponed to the following 1 working days; No additional interest is charged for each interest payment). If the investor exercises the option of resale, the interest payment date for the resale of some bonds will be May 5 days of each year from 2014 to 2016 (in case of legal holidays or rest days, the interest payment will be postponed to 1 working days of the following ; No additional interest will be charged for each interest payment). The debt registration date for the interest payment of the bonds will be processed in accordance with the relevant regulations of the bond registration agency .
8. Credit Rating Agency and Bond Credit Rating
are comprehensively assessed by Joint Rating
. The credit rating of the current corporate bonds isAA + , and the main credit rating of the issuer is AA . 9. Guarantee
This
Company Bond is provided byTianjin Tianshili Group Co., Ltd. full unconditional and irrevocable joint and several liability guarantee . 10. Bond Trustee
Zheshang Securities Co., Ltd. .
11. Capital Verification of Raised Funds Confirmation
The total amount of bonds issued in this period is RMB 3
.2 billion yuan. The net raised funds after deducting the issuance expenses have been remitted to the bank account designated by the issuer on185 , June# , June 13 , 2013. Tianjian Certified Public Accountants (Special General Partnership) hired by the issuer has issued a capital verification report numbered Tianjian Inspection [2013]181 on the availability of the proceeds of the bonds. 12. Repurchase Transaction Arrangement
With the consent of the Shanghai Stock Exchange, a new pledge-type repurchase transaction can be carried out after the listing of the bonds. The specific conversion rate and other matters shall be implemented in accordance with the relevant regulations of the registered company.Section IV Basic Information on Listing and Custody of Bonds
1. Basic Information on Listing of Current Corporate Bonds
With the consent of Shanghai Stock Exchange, this issue of bonds will be listed on Shanghai Stock Exchange from July 2
, 208 , 2013, 206
,. This issue of bonds is referred to as "13 Peak 01 " , and the securities code is "122227 " . The bonds have been applied to the Shanghai Stock Exchange, and new pledge repurchase transactions can be carried out after listing. The specific conversion rate and other matters shall be implemented in accordance with the relevant regulations of China Securities Depository and Clearing Co., Ltd. 2. the basic situation of corporate bond custody According to the bond custody certificate provided by China Securities Depository and Clearing Co., Ltd. Shanghai Branch.
Section V Main Financial Status of the Issuer
Audit of the Financial Reports of the 1. Issuer in the Last Three Fiscal Years
The Financial Reports of the Company 2010
,2011 and
2012have been audited by Tianjian Certified Public Accountants (Special General Partnership), and issued respectively Tianjian Audit [2011]2058 , Tianjian Audit [2012]2018 and Tianjian Audit [2013]2818 standard unqualified audit reports. II. Financial and Accounting Data for the Last Three Years (I) Brief Consolidated Financial Statements
Brief Consolidated Balance Sheet
Unit: yuan
Project
| 2012 July | 31
2011 July | 31
2010 December July | 31
Total Current Assets |
| 598,184,425.67 |
679,445,334.64 |
583,348,017.58 |
Total Non-current Assets |
| 2,180,185,953.50 |
1,959,405,246.64 |
1,572,530,092.02 |
Assets |
| 2,778,370,379.17 |
2,638,850,581.28 |
2,155,878,109.60 |
current liabilities total |
| 1,013,708,681.11 |
893,010,462.35 |
,733, 298,189.60 |
total non-current liabilities |
| 118,223,645.25 |
189,908,882.59 |
164,905,055.88 |
liabilities total |
| 1,131,932,326.36 |
1,082,919,344.94 |
898,203,245.48 |
Total Shareholders' Equity Attributable to Parent Company |
| 1,514,999,218.55 |
1,420,100,618.20 |
1,157,941,656.48 |
|
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11